In vivo quantification of tau can be performed using tau-PET (PET: positron emission tomography). Tau-PET binds to insoluble neurofibrillary tangles, another core pathological feature of AD. Six stages that characterize tau pathology have been established through post-mortem studies1,2 and PET brain imaging.3 This illustration represents the stages of tau pathology measured by PET. Early stages are often accompanied by mild memory dysfunction; middle stages are accompanied by mild cognitive impairment; later stages are observed in individuals with AD dementia.

The figure is reprinted from Therriault J, et al. Nat Aging 2022;2(6):565–535. The content is licensed under a Creative Commons Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/

file_download Download in HQ

Related content

The Complexities and Prospects of Dementia Care in the Future play_circle Video play_circle
The Complexities and Prospects of Dementia Care in the Future

Professor Dr. Matthew Kiernan discusses the limitations of current trial models.

04.12.2024 Alzheimer’s Disease
The Challenges and Potential of Clinical Trials in Dementia Research play_circle Video play_circle
The Challenges and Potential of Clinical Trials in Dementia Research

Professor Dr. Matthew Kiernan discusses the limitations of current trial models.

12.11.2024 Alzheimer’s Disease
image Image Stroke, migraine, AD and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
Highlights from the Global Burden of Disease 2021 Study

Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021

25.07.2024 Alzheimer’s Disease